3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Psoriasis
1
Lymphoma, Follicular
1
Interventions
Rituximab
67
Cyclophosphamide
39
Vincristine
33
Prednisone
31
Doxorubicin
25
Lenalidomide
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Peripheral Blood Stem Cell Transplantation
10
Filgrastim
10
Etoposide
10
Prednisolone
8
tofacitinib
7
obinutuzumab
6
ibritumomab tiuxetan
6
fludarabine
6
VAP-cyclo protocol
6
Mitoxantrone
6
Methylprednisolone
6
Deoxycholic Acid
6
Cytarabine
6
Melphalan
5
Dexamethasone
5
Carmustine
5
ibrutinib
4
fludarabine phosphate
4
R-CHOP protocol
4
Methotrexate
4
Interferon-alpha
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
Anti-Infective Agents, Local
×
Clear all
NCT01313221
2017-03-15
REFINE
Amgen
Phase 3
Completed
310 enrolled
32 charts